Nivolumab/Ipilimumab Combination Extends Survival for Patients with Melanoma

TOP - August 2017, Vol 10, No 3 - Melanoma, AACR News, Conference Correspondent
Phoebe Starr

Washington, DC—The combination of nivolumab plus ipilimumab improved survival compared with ipilimumab alone in patients with previously untreated advanced melanoma, according to updated results of the phase 3 CheckMate-067 clinical trial presented at the 2017 meeting of the American Association for Cancer Research. A descriptive analysis suggested that the combination was superior to nivolumab monotherapy, although that was not a prespecified end point of the study.

“The combination did better across all relevant subgroups. Median duration of response and time to subsequent therapy are not yet reached for the combination. The safety profile was consistent with earlier reports,” said lead investigator James Larkin, FRCP, PhD, Consultant Medical Oncologist, Royal Marsden Hospital, London, UK.

Despite the generally favorable results for the combination of the 2 immune checkpoint inhibitors, Dr Larkin said findings are speculative at present and do not reflect a new standard of care. Increased costs and toxicity are concerns, and an individualized approach is needed for each patient, he noted.

CheckMate-067 is the first phase 3 clinical trial to demonstrate survival outcomes with a combination of nivolumab plus ipilimumab. The regimen was approved by the FDA in 2015 after trial investigators reported extended progression-free survival in patients who were treated with this therapy.

The trial randomized 945 patients with untreated advanced melanoma 1:1:1 to treatment with nivolumab plus ipilimumab, nivolumab with ipilimu­mab-matched placebo, or ipilimumab with nivolumab-matched placebo. Treatment was continued until there was evidence of progressive disease or unacceptable toxicity. Patients were stratified according to the presence of BRAF mutation, M stage, and level of PD-L1 expression. The co-primary end points were progression-free survival and overall survival in an intent-to-treat analysis.

At a minimum follow-up of 28 months, median overall survival was 20 months for ipilimumab and not yet reached for the nivolumab monotherapy or the nivolumab plus ipilimumab combination (P <.0001 for ipilimumab vs the combination). Subsequent systemic therapy was needed by 32% of patients in the combination arm, 44% in the nivolumab monotherapy arm, and 62% in the ipilimumab arm. Two-year overall survival rates were 64% for the combination, 59% for nivolumab, and 46% for ipilimumab. Median progression-free survival was 11.7 months, 6.9 months, and 2.9 months, respectively. Objective response rates were 58.9%, 44.6%, and 19%, respectively. Complete response rates were 12.1%, 9.8%, and 2.2%, respectively. Median duration of response was not yet reached for the combination, 31.1 months for nivolumab, and 18.2 months for ipilimumab.

These data suggest that patients with a BRAF mutation, and those with elevated PD-L1 expression, might benefit more from the combination, but this remains speculative, Dr Larkin told listeners.

The safety profile was consistent with earlier experience using both drugs. The rate of grade 3/4 adverse events was higher in the combination arm; 58.5% versus 20.8% in the nivolumab arm and 27.7% in the ipilimumab arm. Most adverse events were manageable and resolved within 3 to 4 weeks. Just under 40% of patients receiving combination therapy stopped treatment because of adverse events.

Responding patients who stopped combination therapy continued to do well. The objective response rate was 70% among those who discontinued combination therapy because of adverse events, and median overall survival was not reached in this group of patients.

Four treatment-related deaths were reported; 2 of these deaths were included in previous reports of the trial. The 2 new deaths, which both occurred in the combination arm, were associated with cardiomyopathy and liver necrosis and occurred more than 100 days following their last treatment.

Suzanne L. Topalian, MD, Professor of Surgery and Oncology and Director, Johns Hopkins University School of Medicine; Melanoma Program, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, noted that immunotherapy combinations represent an active area of research, with hundreds of ongoing trials. She said that identifying biomarkers for response is a pressing need for patient selection for immunotherapy.

Related Items
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Geriatric Cancer
Enzalutamide or Apalutamide Added to ADT Are 2 New Options for Hormone-Sensitive Prostate Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Prostate Cancer
Practice-Changing Results: Olaparib Maintenance Therapy Extends Progression-Free Survival in Metastatic Pancreatic Cancer with BRCA Mutations
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Pancreatic Cancer
Noteworthy Numbers: Melanoma
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Melanoma, Noteworthy Numbers
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Melanoma
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Renal-Cell Carcinoma
Last modified: September 9, 2019